Search
Skip to Search Results- 3Obesity
- 2Hyperlipidemia
- 1Cardiometabolic syndrome
- 1Metabolizing enzymes
- 1Metformin
- 1Roux-en-Y gastric bypass
-
Fall 2012
Cardiometabolic syndrome refers to a clustering of several risk factors for cardiovascular disease; obesity and hyperlipidemia are two underlying disorders associated with the syndrome. An often overlooked aspect of these conditions is the effect that they may have on the pharmacokinetics of...
-
The Effects of Elements of Cardiometabolic Syndrome on Metformin Disposition: Obesity and Hyperlipidemia
DownloadFall 2015
The influences of obesity, Roux-en-Y gastric bypass bariatric (RYGB) surgery and hyperlipidemia on metformin pharmacokinetics (PK) were investigated. A sensitive and novel HPLC-UV reverse phase assay method was developed and utilized. Detection and mass characterization for metformin metabolites...
-
Spring 2016
The prevalence of obesity worldwide has increased in the last few decades. The risk of obesity comes from its association with various clinical diseases especially cardiovascular diseases and diabetes. In this thesis, we assessed the expression of some drug metabolizing enzymes and transport...